TW273548B - - Google Patents

Info

Publication number
TW273548B
TW273548B TW083107897A TW83107897A TW273548B TW 273548 B TW273548 B TW 273548B TW 083107897 A TW083107897 A TW 083107897A TW 83107897 A TW83107897 A TW 83107897A TW 273548 B TW273548 B TW 273548B
Authority
TW
Taiwan
Prior art keywords
nitrogen
alkylene
bond
membered heterocyclic
heterocyclic ring
Prior art date
Application number
TW083107897A
Other languages
English (en)
Chinese (zh)
Inventor
Ann Mikowski Tamara
Original Assignee
Ono Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ono Pharmaceutical Co filed Critical Ono Pharmaceutical Co
Application granted granted Critical
Publication of TW273548B publication Critical patent/TW273548B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/08Vasodilators for multiple indications
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TW083107897A 1993-08-26 1994-08-29 TW273548B (OSRAM)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US11190693A 1993-08-26 1993-08-26

Publications (1)

Publication Number Publication Date
TW273548B true TW273548B (OSRAM) 1996-04-01

Family

ID=22341063

Family Applications (1)

Application Number Title Priority Date Filing Date
TW083107897A TW273548B (OSRAM) 1993-08-26 1994-08-29

Country Status (11)

Country Link
US (1) US5525604A (OSRAM)
EP (1) EP0640599B1 (OSRAM)
JP (1) JPH0789958A (OSRAM)
KR (1) KR100204433B1 (OSRAM)
CN (1) CN1109055A (OSRAM)
AT (1) ATE163647T1 (OSRAM)
CA (1) CA2130878C (OSRAM)
DE (1) DE69408750T2 (OSRAM)
DK (1) DK0640599T3 (OSRAM)
ES (1) ES2114662T3 (OSRAM)
TW (1) TW273548B (OSRAM)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9325217D0 (en) * 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
JP2000507224A (ja) * 1996-03-08 2000-06-13 スミスクライン・ビーチャム・コーポレイション Csaid化合物の血管形成の抑制物質としての使用
DE19644228A1 (de) * 1996-10-24 1998-04-30 Merck Patent Gmbh Thienopyrimidine
KR100239800B1 (ko) * 1996-11-28 2000-03-02 손경식 4,5-디아미노 피리미딘 유도체 및 이의 제조방법
GB2338957B (en) * 1997-02-19 2001-08-01 Berlex Lab N-heterocyclic derivatives as nos inhibitors
US6432947B1 (en) 1997-02-19 2002-08-13 Berlex Laboratories, Inc. N-heterocyclic derivatives as NOS inhibitors
IN188411B (OSRAM) 1997-03-27 2002-09-21 Yuhan Corp
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
AU748087B2 (en) * 1998-02-17 2002-05-30 Tularik Inc. Anti-viral pyrimidine derivatives
DE19819023A1 (de) * 1998-04-29 1999-11-04 Merck Patent Gmbh Thienopyrimidine
KR100272471B1 (ko) 1998-11-17 2000-11-15 김선진 신규의 피리미딘 유도체 및 그의 제조방법
AU3078000A (en) * 1999-01-25 2000-08-07 Zenyaku Kogyo Kabushiki Kaisha Heterocyclic compounds and antitumor agents containing the same as the active ingredient
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
KR100546992B1 (ko) * 1999-04-09 2006-02-01 씨제이 주식회사 4,5-다이아미노 피리미딘 유도체 및 이의 제조방법
US7037916B2 (en) 1999-07-15 2006-05-02 Pharmacopeia Drug Discovery, Inc. Pyrimidine derivatives as IL-8 receptor antagonists
CN102584799A (zh) * 1999-09-16 2012-07-18 田边三菱制药株式会社 含氮的6-员芳香环化合物
AU7683500A (en) 1999-10-12 2001-04-23 Takeda Chemical Industries Ltd. Pyrimidine-5-carboxamide compounds, process for producing the same and use thereof
WO2001047934A1 (de) * 1999-12-24 2001-07-05 Bayer Aktiengesellschaft Isoxazolopyrimidinone und ihre verwendung
US6943161B2 (en) * 1999-12-28 2005-09-13 Pharmacopela Drug Discovery, Inc. Pyrimidine and triazine kinase inhibitors
US6410726B1 (en) 2000-01-12 2002-06-25 Tularik Inc. Arylsulfonic acid salts of pyrimidine-based antiviral
US6525051B2 (en) 2000-03-27 2003-02-25 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
ATE469132T1 (de) 2000-07-24 2010-06-15 Krenitsky Pharmaceuticals Inc Substituierte 5-alkinyl-pyrimidine mit neurotropher wirkung
IT1318674B1 (it) * 2000-08-08 2003-08-27 Nicox Sa Faramaci per l'incontinenza.
WO2002047690A1 (en) * 2000-12-12 2002-06-20 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
US6716851B2 (en) 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
US20040127502A1 (en) 2001-01-31 2004-07-01 Synaptic Pharmaceutical Corporation Use of GAL3 antagonist for treatment of depression
US7081470B2 (en) 2001-01-31 2006-07-25 H. Lundbeck A/S Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
JP4166991B2 (ja) * 2001-02-26 2008-10-15 田辺三菱製薬株式会社 ピリドピリミジンまたはナフチリジン誘導体
CN1310907C (zh) 2001-04-27 2007-04-18 全药工业株式会社 杂环化合物和以其为有效成分的抗肿瘤药
US6982259B2 (en) 2002-04-30 2006-01-03 Schering Aktiengesellschaft N-heterocyclic derivatives as NOS inhibitors
RU2005102586A (ru) 2002-07-02 2005-09-20 Ф.Хоффманн-Ля Рош Аг (Ch) 2,5-замещенные производные пиримидина в качестве антагонистов ix рецептора ccr-3
AU2005244104B2 (en) * 2004-05-08 2012-03-15 Novartis International Pharmaceutical Ltd. 4,5-disubstituted-2-aryl pyrimidines
EP1812424A4 (en) 2004-11-17 2009-07-08 Miikana Therapeutics Inc Kinase Inhibitors
JP5089377B2 (ja) 2005-03-11 2012-12-05 全薬工業株式会社 複素環式化合物を有効成分とする免疫抑制剤及び抗腫瘍剤
US20060293343A1 (en) * 2005-05-18 2006-12-28 Asahi Kasei Pharma Corporation Pyrimidine derivatives
WO2006123639A1 (ja) * 2005-05-18 2006-11-23 Asahi Kasei Pharma Corporation ピリミジン誘導体
KR101487027B1 (ko) * 2005-09-30 2015-01-28 미카나 테라퓨틱스, 인크. 치환된 피라졸 화합물
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
JP2010529193A (ja) * 2007-06-11 2010-08-26 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
WO2009064388A2 (en) * 2007-11-09 2009-05-22 Liu Jun O Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
CN102143951A (zh) * 2008-09-04 2011-08-03 田边三菱制药株式会社 三取代嘧啶化合物及其作为pde10抑制剂的用途
AU2011255218B2 (en) 2010-05-21 2015-03-12 Infinity Pharmaceuticals, Inc. Chemical compounds, compositions and methods for kinase modulation
CA2840883C (en) * 2011-07-07 2019-07-16 Merck Patent Gmbh Substituted azaheterocycles
US8785470B2 (en) 2011-08-29 2014-07-22 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
TW201605832A (zh) 2013-12-10 2016-02-16 克立弗生物科學公司 作為p97錯合物之抑制劑之單環嘧啶/吡啶化合物
HRP20201384T1 (hr) 2014-01-01 2020-11-27 Medivation Technologies Llc Spojevi i postupci njihove upotrebe
WO2015109285A1 (en) 2014-01-20 2015-07-23 Cleave Biosciences, Inc. FUSED PYRIMIDINES AS INHIBITORS OF p97 COMPLEX
CN105294661B (zh) * 2015-07-27 2017-10-24 西南大学 5‑氟尿嘧啶苯并咪唑类化合物及其制备方法和应用
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3992320A (en) * 1974-08-24 1976-11-16 Basf Aktiengesellschaft Manufacture of a modified titanium component for catalysts of the Ziegler-Natta type
US4032523A (en) * 1975-03-03 1977-06-28 Sterling Drug Inc. 4-amino (or halo or hydroxy or hydrazino)-2-(pyridinyl)pyrimidines
US3992380A (en) * 1975-03-03 1976-11-16 Sterling Drug Inc. 5,8-Dihydro-5-oxo-2-(4-or 3-pyridinyl)pyrido[2,3-d]pyrimidine-6-carboxylic acids and esters
US4018770A (en) * 1975-03-03 1977-04-19 Sterling Drug Inc. N-(2-(pyridinyl)-4-pyrimidinyl)-aminomethylenemalonates and analogs
DE3922735A1 (de) * 1989-07-11 1991-01-24 Hoechst Ag Aminopyrimidin-derivate, verfahren zu ihrer herstellung, sie enthaltende mittel und ihre verwendung als fungizide
US5728704A (en) * 1992-09-28 1998-03-17 Pfizer Inc. Substituted pyridmidines for control of diabetic complications
US5318975A (en) * 1993-02-16 1994-06-07 Berlex Laboratories, Inc. 5-pyrimdineamine derivatives

Also Published As

Publication number Publication date
DE69408750D1 (de) 1998-04-09
CA2130878C (en) 1999-03-23
JPH0789958A (ja) 1995-04-04
EP0640599A1 (en) 1995-03-01
ATE163647T1 (de) 1998-03-15
ES2114662T3 (es) 1998-06-01
CN1109055A (zh) 1995-09-27
KR100204433B1 (ko) 1999-06-15
CA2130878A1 (en) 1995-02-27
US5525604A (en) 1996-06-11
DK0640599T3 (da) 1998-09-28
DE69408750T2 (de) 1998-07-23
KR950005825A (ko) 1995-03-20
EP0640599B1 (en) 1998-03-04

Similar Documents

Publication Publication Date Title
TW273548B (OSRAM)
AU632163B2 (en) 10-(1-hydroxyethyl)-11-oxo-1-azatricyclo(7.2.0.03,8)undec-2- ene-2-carboxylic acid derivatives
TW274541B (OSRAM)
IL135537A0 (en) Substituted fused heterocyclic compounds
IL90336A (en) N-heterocyclic-4- guanylalkylbenzamide protease inhibitors
GR3024979T3 (en) Di(meth)acrylates with cyclic carbonate groups
PH31303A (en) Piperazine derivatives.
TW331558B (en) Antimigraine 1,2,5-thiadiazole derivatives of indolylalkyl-pyridinyl and pyrimidinylpiperazines
AU2508888A (en) New Peroxycarboxilyc amine derivatives
AU3189289A (en) Beta-carbonyl-carboxyamides of 1,3-thiazolidines
AU2175083A (en) 2-(substituted amino)-pyrimid-4-one derivatives
TW288013B (OSRAM)
FI875650A0 (fi) Penemderivat, deras framstaellning och anvaendning.
AU1881388A (en) Certain 1,2-benzisoxazole and 1,2-benzisothiazole derivatives
ES2112489T3 (es) Derivados carboxilato que presentan una actividad inhibidora de la fosfolipasa a2.
GB9015485D0 (en) Heterocyclic derivatives
TW277059B (OSRAM)
ES2055094T3 (es) Utilizacion de poliaminas oxidadas, en particular nn'-bis-(3-propionaldehido)-1-4-diaminobutano (dialdehido espermina) como agentes inmunosupresores.
IL77601A (en) Propanol derivatives
TW257758B (en) Piperazine derivatives (1)